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ABSTRACT 
SINGLE LIQUID-LIQUID EXTRACTION OF 
DELTA-9-TETRAHYDROCANNABINOL AND 
11-NOR-CARBOXY-DELTA-9-TETRAHYDROCANNABINOL 
AT AN ACIDIC PH 
by Meghan Ann Tanner 
August 2012 
Because of the high occurrence of marijuana usage in the workplace and in 
driving under the influence cases, it is important to test for both A-9-THC and A-9-THCA 
in order to determine current and recent usage. The laboratory preparation and analysis of 
A-9-THC and A-9-THCA in urine should be as cost and time efficient as possible. 
Current extraction of A-9-THC and A-9-THCA from urine requires two separate 
techniques for each. Because A-9-THC is nonacidic, while A-9-THCA is acidic, the 
extractions involve two separate pH levels, while GC/MS analysis requires two separate 
methods. This separation requires a great deal of time and materials. 
This experiment focused on eliminating the need for two separate extractions and 
analyses of A-9-THC and A-9-THCA. Both were subjected to simultaneous acidic 
extraction with hexane:ethyl acetate (4: 1). 
An F-ratio test determined that the dual extraction of A;-9-THC and A-9-THCA 
gave concentrations that had no significant differences. The F-ratio for A-9-THC 
concentrations was 0.191, while the F-ratio for A-9-THCA concentrations was 0.021. 
Both fell under the critical value was 5.08 for a 0.01 level of significance. This showed 
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that the concentrations of .!\-9-of F for the analysis of variance from the table which THC 
and .!\-9-THCA calculated for each sample's three aliquots were all significantly similar. 
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CHAPTER I 
INTRODUCTION 
1 
Forensic toxicology is the study of toxic substances encountered in the course of 
judicial investigations (Tebbett, 1994). The area involves analysis of drugs and other 
toxic substances, including their identification and quantification, often from post mortem 
samples. Interpretation of the information gained from analysis is necessary to determine 
if the compounds may have been the cause or a contributing factor of the incident under 
investigation and can aid in verifying or denying claims made by suspects or victims. 
These incidents may include deaths from overdoses of these drugs or toxins or accidents 
caused by intoxication of persons involved. Additionally, many companies are moving 
toward the use of drug testing of their employees for both pre-employment qualifications 
and at random intervals. Marijuana is the most commonly detected drug of abuse in 
workplace urine drug screens (Manno, 2001). Forensic laboratories may also handle this 
type of drug testing. Drug abuse has increased globally and has been recognized as a 
major concern by recent government administrations (Tebbett, 1994). Forensic 
toxicology has aided overall public health with the recognition of the widespread use and 
abuse of drugs and has led to efforts nationally and internationally to control the 
availability of these substances (Ekman, 2009). 
Marijuana is the common name for the dried leaves and flowers of the plant 
Cannabis sativa (Hoffman, 2007). Hashish and hashish oil are produced from the resins 
of the plant. Resin is a viscous substance excreted by cannabis flowering buds and 
contains the highest concentration of Ll-9-THC. The psychoactive chemicals produced by 
Cannabis sativa may vary in concentrations, with as low as 1 % in low-grade marijuana to 
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up to 50% in hashish oils. Marijuana is considered to be the most illicit drug of abuse 
worldwide (Vlase, 2010). Marijuana compounds are the most frequently detected 
substance in cases of driving under the influence of drugs, thus very important for 
forensic toxicologists. A recent study by the United States Substance Abuse and Mental 
Health Services Administration showed that 95 million people 12 years old or older have 
tried marijuana at least once. Additionally, 14.6 million people used marijuana in the 
month prior to the survey, and 4.8 million people used it on days in that month (Hoffman, 
2007). 
Marijuana has been used for more than 4000 years in a wide variety of ways, such 
as for its fiber and seed, as well as its psychoactive effects. Fibers from the plant can be 
used to make textiles such as rope and clothing. The seeds produced from marijuana have 
historically been used as food and as a source of oils. Its psychoactive properties are used 
both for medicinal and recreational purposes. Its earliest medicinal uses date as far back 
as 3000 B.C. in China and India, where its uses included as an anesthetic and for helping 
to increase appetite. Marijuana was brought to America from Europe by early settlers to 
harvest for its fibers in the early 1600s. Its medicinal properties were accepted by medical 
professionals in Western countries around 1839. The abuse of marijuana surfaced and 
became a concern to U.S. government agencies by 1935. The Marijuana Tax Act of 1937 
added heavy taxes on the sale of marijuana. However, in 1942, during WWII, Japan cut 
off its hemp fiber supply to the United States, forcing the U.S. to reverse its policies on 
marijuana cultivation. The government quickly planted a 350,000 acre crop of marijuana 
to make up for their loss in fibers produced from the plant. Marijuana's use in the United. 
States as a psych9active drug became widespread in the 1960s and 70s. The 
Comprehensive Drug Abuse Act of 1970 finally made marijuana farming and use illegal 
(Musto, 1991). Today, many states have legally instituted the use of marijuana for its 
medical use, but the US federal government still classifies marijuana as a Schedule I 
drug. 
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For analytical examination of cannabinoids in urine samples, a sample preparation 
is necessary. This involves cleavage of conjugates, extraction, and derivatization. The 
active compound of marijuana is 8-9-THC, which is metabolized in the body to 11-0H-
THC and 8-9-THCA. 8-9-THCA and its glucuronide conjugate have been identified as 
the major end products of biotransformation of 8-9-THC in the body and thus are most 
often used for detection to indicate that a person has ingested marijuana (Huestis, 2002). 
8-9-THCA is detectable in urine after a much longer period of time than that of 8-9-THC 
or 11-0H-THC, because 8 -9-THCA concentrations gradually rise above 8-9-THC levels 
overtime. However, 8-9-THC and 11-0H-THC concentration levels in urine can 
establish a timeline of when a person has last ingested marijuana. This is important 
information because the psychoactive components of marijuana ingestion alter 
psychomotor and psychological performance. These performance alterations are most 
prominent 1-2 hours after smoking and subside at about 4 hours after ingestion (Kelly 
1992). 
Cleavage of cannabinoids from their glucuronide bonds occurs with alkaline or 
enzymatic hydrolysis. The cannabinoids must then be extracted from their biological 
source. The extraction may be performed with either liquid-liquid extraction or solid 
phase extraction. Liquid-liquid extraction is the most frequently used separation 
technique in toxicology laboratories around the world (Levine 2006). Urine can be easily 
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partitioned with an organic solvent after a pH adjustment of the liquid with a buffer, acid, 
or base. The solvent most often used for drug analysis is the very nonpolar hexane 
because of the polarity of most drugs. The basis for liquid-liquid extraction is the use of 
two liquids that are immiscible from one another, water and an organic solvent. The 
extraction will be either basic or acidic depending on the pKa of the drug. Solid phase 
extractions use a stationary phase which is a column made of silica that has an affinity for 
the analyte of interest in the sample. The sample is forced through the column using a 
vacuum and the drug settles throughout the column, while the unwanted interferences are 
washed out with an organic solvent. A buffered organic solvent is then sent through the 
column to elute the analytes of interest. With no extraction, Gas Chromatography/Mass 
Spectrometry analysis will encounter problems, such as buildup of interferences on the 
column, leading to inefficiency. 
Efficiency of extraction techniques in amount of time and amount of materials is 
important for forensic toxicology laboratories. Current extractions of cannabinoids 
involve separate extractions of L\.-9-THC and L\.-9-THCA at two different pH levels. This 
study focused on developing a single extraction of L\.-9-THC and L\.-9-THCA in order to 
save both time and materials. 
CHAPTER II 
REVIEW OF LITERATURE 
Marijuana and its Cannabinoids 
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Marijuana is a complex drug, containing over 421 different chemical compounds, 
61 of which are naturally occurring phytocannabinoids (Huestis, 2002). The term, 
phytocannabinoid, is given to the class of hydrocarbon compounds that contain oxygen 
and 21 carbons, produced solely by the cannabis plant. Phytocannabinoids are in the class 
of compounds called cannabinoids, which also includes both naturally occurring and 
synthetic compounds with similar effects or structure to that of phytocannabinoids 
(Pertwee, 2005). Marijuana contains four psychoactive ingredients, including A-9-
tetrahydrocannabinol (A-9-THC), cannabidiol, cannabinol, and cannabichromene. Of 
these four, A-9-THC is the most active compound. Its structure was finally elucidated in 
1964 as a tricyclic 21-carbon structure with two chiral centers. The neutral compound is a 
volatile with high lipid solubility and low water solubility (Huestis, 2002). 
Marijuana is most often ingested by smoking. Cannabinoids are initially absorbed 
in the lungs and metabolized in the liver, most often to side chain hydroxylated 
derivatives. The main active metabolite of A-9-THC is 11-hydroxy-A-9-
tetrahydrocannabinol (11-0H-THC) and is produced by hydroxylation by cytochrome 
P450 enzymes. Oxidation of the active 11-0H-THC produces the inactive metabolite 11-
nor-9-carboxy-delta-9-tetrahydrocannabinol (A-9-THCA) (Huestis, 2002). A-9-THCA is 
then metabolized by conjugation to glucuronide, forming a more water soluble 
compound, which is thus easily excreted from the body by the kidneys in urine and feces 
(Vlase, 2010). Approximately 20% of a dose of A-9-THC is excreted in the urine as A-9-
THCA, while ~-9-THC and 11-0H-THC have also been identified in urine as 
glucuronide conjugates (Huestis 2002). 
CH3 COOH 
CsH.. 
THC 11-0H-THC l THC-C<>Oti 
Glucuronlde 
Figure 1. Metabolism of ~-9-THC. 
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Manno et al. (2001) determined the temporal relationship between marijuana 
ingestion and cannabinoids excretion patterns. Eight human subjects with a self-reported 
history of light marijuana usage took part in the study. A marijuana cigarette was smoked 
by each at computer paced intervals. Each subject was instructed to inhale for three 
seconds, hold their breath for 20 seconds, exhale, and relax for 34 seconds before the next 
inhalation. Eight puffs were administered over 7 .6 minutes. Urine samples were acquired 
and analyzed via GC/MS after appropriate sample preparations. Peak urinary ~-9-THC 
levels were reached two hours after inhalation. ~-9-THC concentrations fell below the 
limit of detection after five hours. Mean peak concentrations in urine samples of 11-0H-
THC were achieved at three hours after ingestion. 11-0H-THC was detectable in urine as 
soon as five minutes after smoking. Levels did not return to baseline by the end of the 
study, at eight hours. ~-9-THCA was detected in the urine four hours after smoking and 
remained until the end of the study. 
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Analysis of Cannabinoids 
Because cannabinoids are primarily excreted in the urine as glucuronide 
conjugates, urine samples must be subjected to hydrolysis to cleave the glucuronide 
bonds in order for the compounds to be analyzed via Gas Chromatography/Mass 
Spectrometry (GC/MS). This may be attained by an enzymatic or alkaline hydrolysis. 
However, alkaline hydrolysis and some enzymatic approaches will not effectively cleave 
the ether bonds of 8-9-THC or 11-0H-THC from their glucuronide conjugates (Huestis, 
2002). On the other hand, both enzymatic and alkaline hydrolysis methods are successful 
in the release of the ester-linked glucuronide of 8-9-THCA. Several different enzymes 
may be used for hydrolysis of glucuronide bonds, including those from the sources of 
mollusk, bacteria, bovine, and limpet, all with varying pH levels for maximal efficiency. 
Different hydrolysis methods for cannabinoid glucuronides have been compared by 
Kemp et al. (1995), including alkaline hydrolysis and p-glucuronidase enzymatic 
hydrolysis from both the E. coli bacteria and H. pomatio mollusk sources. Urine was 
collected and analyzed from a male subject who was administered one marijuana 
cigarette containing 3.58% 8-9-THC at a computer controlled pace. Concentrations of 8-
9-THC, 11-0H-THC, and 8-9-THCA were measured. In all hydrolysis methods 
analyzed, deuterated internal standards were added for their comparison with the native 
cannabinoid ions in MS analysis. 8 -9-THC-D3, 11-0H-THC-D3, and 8-9-THCA-D3 
were added in concentrations of 30 ng/mL in methanol solution. 
To adjust 1.0 mL urine aliquots to an appropriate pH for maximal enzymatic 
activity, 1.0 mL O. lM potassium phosphate buffer was added. As recommended from the 
manufacturer, p-glucuronidase from mollusks required a pH of 5.0 while the bacterial 
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source required a pH of 6.8. If necessary, an additional 50 mM phosphoric acid was 
added dropwise to adjust pH to 5.0, and O. lN NaOH was added dropwise to adjust pH to 
6.8. Hydrolysis was achieved by adding 200 µL of a 25,000-unit/mL solution of each 
P-glucuronidase enzyme in 0.1 M potassium phosphate buffer (pH 5.0 or 6.8). Samples 
were then gently vortexed and subjected to 16-hour incubation at 37°C. For alkaline 
hydrolysis, the urine was adjusted to pH 13 .0 with 0.5 mL 2N NaOH followed by gentle 
vortexing and 16-hour incubation at 37°C. After hydrolysis, each sample was subjected 
to extraction and derivatization before analysis on GC/MS. A control group was also 
included which does not involve any hydrolysis before extraction and derivatization. 
Each hydrolysis method was performed in triplicate for maximal conclusion. 
The results showed that the concentration of freed 8-9-THC, 11-0H-THC, and 
8-9-THCA were affected by the method of hydrolysis. The control group with no 
hydrolysis produced no 8-9-THC and very low concentrations of 11-0H-THC. The 
concentrations of 8-9-THCA were above the detection limit for urine, showing that it 
was successfully cleaved by the addition of the 2N NaOH added during extraction. The 
alkaline hydrolysis showed no concentrations of 8-9-THC or 11-0H-THC and similar 
8-9-THCA concentrations to that of the control group. Enzymatic hydrolysis with E. coli 
P-glucuronidase showed much greater levels of 8-9-THC and 11-0H-THC 
concentrations compared to the alkaline hydrolysis and the enzymatic hydrolysis with H. 
pomatia P-glucuronidase. 8-9-THCA levels were slightly higher with hydrolysis by H. 
pomatia. 
Current extraction techniques involve two separate extractions for the acidic and 
nonacidic fractions. Kemp et al. (1995) has described a technique for separate extraction 
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of the nonacidic Li-9-THC and acidic Li-9-THCA in urine samples. For the extraction of 
the nonacidic portion containing Li-9-THC, the samples were made basic (pH 13.0) by 
adding 0.5 mL 2N NaOH. Four milliliters of hexane-ethyl acetate (7:1) was added, and 
samples were mixed gently on a rotator for 15 minutes followed by centrifugation at 2800 
rpm for five minutes. The solvent layer, which contains the neutral Li-9-THC, was then 
transferred to a clean tube and evaporated to dryness. Next, 20 µL BSTF A plus one 
percent TMCS was added and incubated for 15 minutes prior to injection on GC/MS. For 
the separate extraction of the acidic Li-9-THCA, the urine was acidified with the addition 
of 1.0 mL lN HCl to adjust the pH to 4-5. Again, four mL hexane-ethyl acetate (7:1) was 
added, samples mixed gently on a rotator for five minutes, followed by centrifugation at 
2800 rpm for five minutes. The solvent layer containing the acidic Li-9-THCA was placed 
in a new tube, dried down, derivatized with 20 µL BSTFA plus 1 % TMCS and incubated 
at 37°C for 15 minutes before injection on GC/MS. 
In addition to separate extractions for the nonacidic and acidic portions, Kemp et 
al. (1995) also used separate GC/MS settings for each, with the nonacidic analysis much 
longer and more complicated. It requires a column temperature of 150°C that is 
maintained for one minute following the injection. The temperature was then raised to 
240°C at 30°C per minute, then held at 240°C for 30 seconds; raised to 280°C at 3°C per 
minute and held for 1.0 minute; raised to 300°C at 30°C per minute and held for 1.0 
minute. Total program time was 20.5 minutes. The acidic analysis requires an initial 
column temperature of 200°C for 1.0 minute following injection, then increased to 300°C 
at 30°C per minute where it was held for 5.0 minutes with a total program time of 9.33 
minutes. 
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In another study, different techniques were compared for the extraction of 8-9-
THC. Both alkaline and enzymatic hydrolysis before extraction with hexane:ethyl acetate 
(4: 1) were compared. The alkaline extraction using NaOH was not successful in breaking 
the glucuronide bonds in order to successfully analyze 8-9-THC. No 8-9-THC was 
recovered during analysis. Two different enzymatic approaches with P-glucuronidase 
were tested. The first was an acidic extraction at pH 6.5 using sodium phosphate. 
Samples were treated with sodium phosphate before incubation with P-glucuronidase for 
hydrolysis. The second was a basic extraction using sodium hydroxide. The samples 
were again buffered with sodium phosphate before enzymatic hydrolysis, then adjusted to 
a basic pH with sodium hydroxide before extraction. Upon analysis, it was shown that 
there was no significant difference in the recovery of 8-9-THC using either the acidic or 
basic extraction after enzymatic hydrolysis with p-glucuronidase. The percentage of 
recoveries for the acidic extraction was slightly higher than the extraction at a basic pH 
(Harmon, 2010). 
This study attempted to hydrolyze and extract both 8 -9-THC and 8 -9-THCA 
simultaneously from urine at an acidic pH to give the most time and cost efficiency. 
CHAPTER ill 
METHODS AND MATERIALS 
Procedure 
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Fifty urine samples from donors were collected in a previous Institutional Review 
Board (IRB) approved study. Seventeen of these samples were divided into three, 2-mL 
aliquots and treated with sodium phosphate before hydrolysis of i\-9-THC with ~-
glucuronidase. The samples were then treated with sodium hydroxide for hydrolysis of i\-
9-THCA before being extracted at an acidic pH. 
Preparation of Buffer Solution 
The buffer used was 1.0 M, sodium phosphate, pH 6.25. It was made by using 
both monobasic (NaH2P04) and dibasic (Na2HP04) sodium phosphate salts dissolved in 
Type ill deionized water. The buffer was made with the following steps: 
1. 69.00 g of NaH2P04 (Fisher Scientific, Houston, TX) was weighed out and 
placed in a 500 mL Erlenmeyer flask and dissolved to a final volume of 500 mL with 
Type III deionized water. The pH of the solution was 4.5, which was verified with a pH 
meter (Accumet 25CL, Fisher Scientific, Houston, TX). 
2. 134.04 g of Na2HP04 (Fisher Scientific, Houston, TX) was then weighed and 
placed in a 500 mL Erlenmeyer flask and brought to 500 mL with Type III deionized 
water. The pH of the solution was 9.5, which was verified with a pH meter. 
3. The 500 mL of NaH2P04 was added to a 1-L beaker. Measured increments of 
the Na2HP04 were added to the NaH2P04 with a 10-mL volumetric pipette ensuring 
continuous stirring using a magnetic hot plate and stirrer. The pH was measured 
throughout the addition of the monobasic buffer until a pH of 6.25 was achieved. This 
solution was covered with Parafilm and stored at 4 °C until later use. 
Preparation of Sodium Hydroxide Solution 
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Sodium hydroxide (NaOH) was added to each sample in order to cleave the 
glucuronide from ~-9-THCA. 100 mL of the 10 M solution was made with the following 
steps: 
1. 40 g NaOH (Fisher Scientific, Houston, TX) was weighed and placed in a 100 
mL Erlenmeyer flask which was brought to 100 mL with Type I water. 
2. The flask was placed on a magnetic hot plate and a stirring bar added until all 
of the NaOH was dissolved. 
Preparation of ,1-9-THC Standards 
Standards of ~ -9-THC in concentrations of 5, 10, 18, and 50 ng/mL were 
prepared in order to produce a calibration curve for quantitation purposes. This was 
completed through the following steps: 
1. A 1 mg/mL ~-9-THC standard was obtained (Cerilliant, Round Rock, TX) and 
diluted to 0.1 mg/mL by adding 9 mL methanol to 1 mL of the standard. 1 mL of the 0.1 
mg/mL was placed into a new tube and 9 mL methanol added for a concentration of 10 
µg/mL. 1 mL of the 10 µg/mL was placed into a new tube and 9 mL methanol added for a 
concentration of 1 µg/mL. 1 mL of the 1 µg/mL was placed into a new tube and 9 mL 
methanol added for a concentration of 100 ng/mL. 
2. 2 mL of the 10 µg/mL was placed into a new tube and 3 mL methanol added 
for a concentration of 4 µg/mL. 
3. 720 µL of the 4 µg/mL was placed into a new tube and 1.28 mL methanol 
added for a concentration of 1.44 µg/mL. 
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4. 4 mL of the 1 µg/mL was placed into a new tube and 1 mL methanol added for 
a concentration of 800 ng/mL. 
5. 1 mL of the 800 ng/mL was placed into a new tube and 1 mL methanol added 
for a concentration of 400 ng/mL. 
6. 25 µL of the 4 µg/mL and 2 mL clean urine was added to a new tube for a 
concentration of 50 ng/mL. 
7. 25 µL of the 1.44 µg/mL and 2 mL clean urine was added to a new tube for a 
concentration of 18 µg/mL. 
8. 25 µL of the 800 ng/mL and 2 mL clean urine was added to a new tube for a 
concentration of 10 ng/mL. 
9. 25 µL of the 400 ng/mL and 2 mL clean urine was added to a new tube for a 
concentration of 5 ng/mL. 
10. A 100 µg/mL standard of ~-9-THC-D3 was obtained (Cerilliant, Round 
Rock, TX) and diluted to 10 µg/mL by adding 9 mL methanol to 1 mL of the standard. 3 
mL of the 10 µg/mL was placed into a new tube and diluted with 7 mL methanol for a 
concentration of 3 µg/mL. 33 µL of the 3 µg/mL was added to each sample as an internal 
standard so that the equivalent concentration was 50 ng/mL. 
Preparation of Ll-9-THCA Standards 
Standards of ~-9-THCA in concentrations of 5, 20, 80, 200, and 400 ng/mL were 
prepared in order to produce a calibration curve for quantitation purposes. This was 
completed through the following steps: 
1. A 1 mg/mL 8-9-THCA standard was obtained (Cerilliant, Round Rock, TX) 
and diluted to 100 µg/mL by adding 9 mL methanol to 1 mL of the standard. 
2. 320 µL of the 100 µg/mL was placed into a new tube and 680 µL methanol 
added for a concentration of 32 µg/mL. 
3. 500 µL of the 32 µg/mL was placed into a new tube and 500 µL methanol 
added for a concentration of 16 µg/mL. 
4. 400 µL of the 16 µg/mL was placed into a new tube and 600 µL methanol 
added for a concentration of 6.4 µg/mL. 
5. 250 µL of the 6.4 µg/mL was placed into a new tube and 750 µL methanol 
added for a concentration of 1.6 µg/mL. 
6. 250 µL of the 1.6 µg/mL was placed into a new tube and 750 mL methanol 
added for a concentration of 400 ng/mL. 
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7. 25 µL of the 32 µg/mL and 2 mL clean urine was added to a new test tube for a 
concentration of 400 ng/mL. 
8. 25 µL of the 16 µg/mL and 2 mL clean urine was added to a new test tube for a 
concentration of 200 ng/mL. 
9. 25 µL of the 6.4 µg/mL and 2 mL clean urine was added to a new test tube for 
a concentration of 80 ng/mL. 
10. 25 µL of the 1.6 µg/mL and 2 mL clean urine was added to a new test tube 
for a concentration of 20 ng/mL. 
11. 25 µL of the 400 ng/mL and 2 mL clean urine was added to a new test tube 
for a concentration of 5 ng/mL. 
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12. A 100 µg/mL standard of 8-9-THCA-D3 was obtained (Cerilliant, Round 
Rock, TX) and diluted to 10 µg/mL by adding 9 mL methanol to 1 mL of the standard. 25 
µL of the 10 µg/mL was added to each sample as an internal standard so that the 
equivalent concentration was 125 ng/mL. 
Single Extraction of .1-9-THC and.1-9-THCA in Urine Samples using p-glucuronidase 
The dual extraction of 8-9-THC and 8-9-THCA was accomplished by the 
following steps: 
1. 100 µL of p-glucuronidase from E. coli (Thermo Fisher, Houston, TX) was 
added to all standards and samples. 
2. Standards and samples were buffered with 1.0 mL of sodium phosphate (pH 
6.25), vortexed, and incubated at 37°C for three hours for hydrolysis of the 8-9-THC 
glucuronide bonds. 
3. 100 µL sodium hydroxide (10 M) was added to each standard and sample 
followed by incubation at 70°C for one hour for hydrolysis of the 8 -9-THCA glucuronide 
bonds. 
4. 2 mL acetic acid was added to each standard and sample to bring the pH back 
to acidic. 
5. Extraction solvent of 7 mL hexane:ethyl acetate ( 4: 1) was added to each 
standard and sample. 
6. The standard and sample tubes were then capped and placed on a platform 
rotator to be mixed at slow speed to prevent emulsion for one hour. 
7. The standard and sample tubes were then centrifuged at 3000 RPM for 30 
minutes. 
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8. The solvent layers of each standard and sample were then removed and placed 
into new tubes. They were then subjected to evaporation in a Rapidvap (Thermo-Fisher, 
Houston, TX). 
9. The standard and sample tubes were then allowed to cool to room temperature. 
35µL N-Methyl-N-(t-butyldimethylsilyl) trifluoroacetamide (MTBSTFA) + 1 % 
tertbutyldimetheylchlorosilane (t-BDMCS) was then added. 
10. The tubes were again capped and then vortexed before being heated at 70°C 
for one hour for derivitization. 
11. The standards and samples were then allowed to cool to room temperature, 
transferred to autosampler vials with 100 µL inserts, and capped with an electronic 
crimper. 
12. 2 µL of each standard and sample was analyzed using a Gas 
Chromatograph/Mass Spectrometer (Clams 600 EI+, Perkin Elmer, Shelton, CT). 
Gas Chromatograph/Mass Spectrometer Parameters 
1. The instrument used was a PE Autosystem GC with built-in Autosampler and a 
Clams MS 1. 
2. The total duration of the analysis was 15 minutes, with the solvent delay start 
at 0.0 minutes and the solvent delay end at 8.80 minutes. 
3. The autosampler method involved a syringe with a capacity of 5.0 µL. The 
injection volume was 2.0 µL and a normal injection speed was used with four sample 
pumps and no viscosity delay. Two pre-injection solvent washes and eight post-injection 
solvent washes were used 
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4. The oven program had an initial temperature of 100°C with an initial hold of 
1.0 minutes. The ramp rate was l 8°C per minute to 300°C and was held for 2.89 minutes. 
The equilibration time between runs was 0.2 minutes. 
5. The carrier parameters involved a PF1ow-H2 carrier control. The column was 
30.0 meters long and had a diameter of 250 µm. Vacuum compensation was used. The 
flow rate was 0.50 m.Umin. 
6. The valve configuration used a split, with split one set to zero at -0.30 minutes 
and split two set to 50 at 1.0 minutes. 
3. The MS used two functions. Function one was an SIR of the five masses, 357, 
371,374,413, and 416 m/z at 0.010 s dwell, from 10.49 to 12.49 minutes. The ion mode 
was Et and the inter channel delay was at 0.001 seconds 
3. Function two was an SIR of the five masses, 515,518,557,572, and 575 m/z 
at 0.010 s dwell, from 12.79 to 15.0 minutes. The ion mode was Er and the inter channel 
delay was at 0.001 seconds. 
CHAPTERN 
DATA AND RESULTS 
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In a previous Institutional Review Board (IRB) approved study, 50 urine samples 
from anonymous donors who use marijuana regularly were collected and used for the 
purpose of a separate research project. A third party individual distributed collection cups 
and informed consent forms to the anonymous donors to be filled. The cups were 
returned by the third party individual to the laboratory and locked in storage until 
treatment. The IRB form and informed consent form can be found in Appendices A and 
B. 
Seventeen of the 50 samples collected were used for this research. Clean urine 
was also attained and spiked to make 2-mL standards of Ll-9-THC and Ll-9-THCA in 
concentrations of 5, 10, 18, 50 ng/mL and 5, 20, 80, 200,400 ng/mL respectively. Each 
of the 17 samples was divided into three, 2-mL aliquots. These 51 samples and the 
standards were spiked with Ll-9-THC-D3 and Ll-9-THCA-D3 deuterated internal 
standards to give concentrations of 50 ng/mL and 125 ng/mL respectively. Each sample 
and standard was then treated with 100 µL ~-glucuronidase from E.coli for hydrolysis of 
Ll-9-THC. One mL of sodium phosphate buffer, pH 6.25, was then added to create an 
optimum pH environment for hydrolysis of Ll-9-THC with ~-glucuronidase. The samples 
and standards were then incubated at 37°C for three hours. In trial runs, an incubation 
time of 16 hours, or overnight, was tested but showed no difference than that of the 
3- hour incubation. The samples were then treated with 100 µL of sodium hydroxide, 10 
M, before incubation in a water bath at 70°C for 1 hour for the hydrolysis of Ll-9-THCA. 
Two mL acetic acid was then added to each sample and standard to adjust the pH to 
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acidic before extraction with 7 mL Hexane:Ethyl Acetate (4: 1) on a platform rotator for 
one hour followed by centrifugation for 30 minutes. The extraction solvent was then 
removed and dried completely before derivatization at 70°C for one hour with 35 µL N-
Methyl-N-(t-butyldimethylsilyl) trifluoroacetamide (MTBSTFA) + 1 % 
tertbutyldimetheylchlorosilane (t-BDMCS). The standards and samples were then 
analyzed by GC/MS with selective ion monitoring and quantitated for 8-9-THC, 8-9-
THC-D3, 8-9-THCA and 8-9-THCA-D3 using the 357, 371,374,413,416, and 515, 
518,557,572, 575 ions respectively (Figures 2, 3, and 4). 
Each sample' s 8-9-THC and 8-9-THCA peak areas and heights were compared 
to the internal standard's peak areas and heights in order to obtain a ratio. The ratios of 
the standards were used to make calibration curves in order to plot the ratios from each 
sample to obtain their concentration. The calibration curves from the 8-9-THC, 8-9-
THC-D3, 8-9-THCA, and 8-9-THCA-D3 are given in Figures 2, 3, 4, and 5 respectively. 
The concentrations of each sample that were determined using the calibration curves are 
given in Tables 1 and 2. 
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Figure 2. L\-9-THC Chromatogram. L\-9-THC was eluted from the column at 10.92 
minutes (Sample 16-2). 
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Figure 3. ~-9-THCA Chromatogram. ~-9-THCA was eluted from the column at 13.29 
minutes' (Sample 16-2). 
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Figure 4 . .6.-9-lHC and .6.-9-lHCA ion spectra (Sample 16-2). Each sample was quantitated for .6.-9-lHC using the 357, 
371, 374,413, and 416 ions. Samples were quantitated for .6.-9-lHCA using the 515, 518, 557, 572, and 575 ions. 
N 
N 
Compound 1 name: THC 
Correlation coefficient: r = 0.999705, r"2 = 0.999410 
Calibration curve: 0 .0349253 '* x + 0 .0429223 
Response type: Internal Std ( Ref 2 ) . Height'* ( IS Cone. I IS Height ) 
Curve type: Linear. Origin: Exclude , Weighting: Null, Axis trans: None 
1.79 
Response 
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o 11-.-...-.--------------------- ng/ml 5.0 15.0 25 .0 35.0 45.0 
Figure 5. 8-9-THC Calibration Curve. The calibration curve was created by plotting the 
concentrations of the 8-9-THC standards of 5, 10, 18, and 50 ng/mL against the response 
ratios obtained. 
Compound 2 name: THC-03 
Response Factor: 1 
Response type: Internal Std ( Ref 2 ) , Height "' ( IS Cone. / IS Height ) 
Curve type: RF 
1-
Response-
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Figure 6. 8-9-THC-D3 Calibration Curve. The calibration curve shows the response of 
the 8-9-THC-D3 deuterated internal standard that was added to each sample. 
compound 3 name: THCA 
Correlation coefficient r = 0.996442, r"2 = 0.992897 
Calibration curve: a .00750599 ,. x + -0 .0768027 
Response type: Internal Std ( Ref 4 ) , Height• ( IS Cone . / IS Height) 
Curve type: Linear, Origin: Exclude, Weighting: Null , Axis trans: None 
3.01-
Response· 
X 
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X 
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Figure 7. ~-9-THCA Calibration Curve. The calibration curve was created by plotting 
the concentrations of the ~-9-THC standards of 5, 20, 80, 200 and 400 ng/mL against the 
response ratios obtained. 
Compound 4 name: THCA_D3 
Response Factor: 1 
Response type: Internal Std ( Ref 4 ) , Height "' ( IS Cone . / IS Height ) 
Curve type: RF 
Response-
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o ri----...-1 --,1 """--... 1--... 1---1 --,1 """---,,--... , ---1 --,1 ng/ml 
0.0 0.1 0 .2 0.3 0.4 0.5 0.6 0 .7 0 .8 0.9 1.0 
Figure 8. ~-9-THCA-D3 Calibration Curve. The calibration curve shows the response of 
the ~-9-THC-D3 deuterated internal standard that was added to each sample. 
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Table 1 
L1-9-THC Concentrations 
Sample No. Cone. 1 (ng/rnL) Cone. 2 (ng/rnL) Cone. 3 (ng/rnL) 
1. Sample 1 2.91 2.60 2.31 
2. Sample 2 .00 .00 .04 
3. Sample 3 20.87 33.90 38.61 
4 . Sample4 4.66 4.97 6.06 
5. Sample 5 13.74 12.83 12.47 
6. Sample 6 4.51 4.37 4.64 
7. Sample 7 7.97 4.81 11.52 
8. Sample 8 5.96 7.67 10.02 
9. Sample9 6.90 8.40 9.70 
10. Sample 10 4 .28 6.23 5.93 
11. Sample 11 .00 .00 .00 
12. Sample 12 .00 .00 .00 
13. Sample 13 .00 .00 .00 
14. Sample 14 .00 .00 .00 
15. Sample 15 .00 .00 .00 
16. Sample 16 11.80 15.18 11 .57 
17. Sample 17 .00 .00 .01 
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Table 2 
..1-9-THCA Concentrations 
Sample No. Cone. 1 (ng/mL) Cone. 2 (ng/mL) Cone. 3 (ng/mL) 
1. Sample 1 96.32 93.85 92.15 
2. Sample 2 25.33 22.30 25.87 
3. Sample 3 674.02 853.29 922.93 
4. Sample4 86.23 83.70 92.92 
5. Sample 5 304.27 326.71 289.86 
6. Sample 6 41.42 40.79 38.92 
7. Sample 7 30.71 24.32 24.55 
8. Sample 8 30.75 34.25 31.79 
9. Sample 9 30.61 27.11 33.99 
10. Sample 10 50.40 53.34 40.71 
11. Sample 11 45.49 46.94 41.96 
12. Sample 12 36.34 34.38 33.76 
13. Sample 13 51.43 48.56 48.54 
14. Sample 14 42.81 33.80 36.96 
15. Sample 15 100.27 90.27 100.59 
16. Sample 16 190.79 202.44 200.16 
17. Sample 17 102.90 97.29 105.47 
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In order to determine if there were statistically significant differences between 
each of the three concentrations of 8-9-THC and 8-9-THCA calculated for each sample, 
an ANOV A repeated measure within-subjects F-ratio test was completed at a level of 
0.01 significance using SPSS Statistics 18 software. The overall data for 8-9-THC 
concentrations was found to be statistically nonsignificant at 0.01 level of significance 
with F(2,48) = 0.191 , and p = 0.827. Similarly, the overall data for 8-9-THCA 
concentrations was found to be statistically nonsignificant at 0.01 level of significance 
with F(2,48) = 0.021 , and p = 0.979. Comparing these values to the critical value of 5.08 
from the critical values of F table determined that there was no statistical significant 
difference between each concentration (Tables 3 and 4). 
Table 3 
Statistical comparison of !J.-9-THC Concentration Values 
Between Groups 
Within Groups 
Total 
Table4 
Sum of Squares 
25.653 
3222.880 
3248.532 
Df 
2 
48 
50 
Mean Square 
12.826 
67.143 
Statistical comparison of !J.-9-THCA Concentration Values 
Sum of Squares Df Mean Square 
Between Groups 25.653 2 12.826 
F-ratio p 
.191 .827 
F-ratio p 
.191 .827 
Table 4 (continued). 
Within Groups 
Total 
Sum of Squares 
3222.880 
3248.532 
Of 
48 
50 
30 
Mean Square F-ratio p 
67.143 
CHAPTERV 
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Marijuana is considered the most illicit drug of abuse worldwide (Vlase, 2010) 
and is the most commonly detected drug of abuse in workplace urine drug screens 
(Manno, 1995) and cases of driving under the influence of drugs (Vlase, 2010). The 
psychoactive components of marijuana consumption effect psychomotor and 
psychological performance. These effects are most prominent one to two hours after 
smoking and four hours after ingestion (Kelly, 1992). The active compound in marijuana 
is 8-9-Tetrahydrocannabinol {8-9-THC), which is eventually metabolized in the body to 
its major end product, the inactive 11-nor-9-Carboxy-8-9-Tetrahydrocannabinol (8-9-
THCA). 8-9-THC and 8-9-THCA may then undergo conjugation to glucuronide in order 
to become more water soluble and thus more easily excreted in urine (Vlase, 2010). 
Overtime, 8-9-THCA concentrations gradually rise above 8 -9-THC levels in urine, 
allowing a much longer detection time for 8-9-THCA. However, finding high 
concentrations of 8-9-THC in urine suggest recent usage and the person may have been 
under the influence, and thus impaired, at the time of sample collection. Because of the 
high occurrence of marijuana usage in the workplace and in driving under the influence 
cases, it is important to test for both 8 -9-THC and 8-9-THCA in order to determine both 
current and recent usage. Most importantly, the laboratory preparation and analysis of 8-
9-THC and 8-9-THCA in urine should be as cost and time efficient as possible. 
Current extraction of 8-9-THC and 8 -9-THCA from urine followed by analysis 
requires two separate techniques for each of the cannabinoids. Because 8-9-THC is 
nonacidic, while 8-9-THCA is acidic, the extractions of the two involved two separate 
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pH levels, while the analysis on GC/MS requires two separate methods. The nonacidic ll.-
9-THC required a basic pH (13.0) while the ll.-9-THCA required an acidic pH (4-5). 
(Kemp, 1995) This separation requires a great deal of time and materials. 
This experiment focused on eliminating the need for two separate extractions and 
analyses of ll.-9-THC and ll.-9-THCA in order to lower the cost and amount of time 
required. Dual cleavage of ll.-9-THC and ll.-9-THCA from their glucuronide conjugates 
with J3-glucuronidase from E. coli was attempted in trial runs and was only successful in 
hydrolysis of ll.-9-THC. No ll.-9-THCA was recovered when J3-glucuronidase from E. 
coli was used for cleavage from glucuronide. Separate hydrolysis to cleave ll.-9-THC and 
ll.-9-THCA from their glucuronide conjugates was found to be required. /l.-9-THC was 
subjected to hydrolysis by J3-glucuronidase ~rom E. coli at a pH of 6.25, while ll.-9-THCA 
underwent hydrolysis by sodium hydroxide (10 M). Following separate hydrolysis, both 
were subjected to simultaneous acidic extraction with hexane:ethyl acetate ( 4: 1 ). This 
method proved to be efficient in recovering both ll.-9-THC and ll.-9-THCA from urine. 
Each urine sample was divided into three 2-mL aliquots for maximal conclusion. 
A statistical comparison between each sample's ll.-9-THC and ll.-9-THCA concentrations 
was made to determine if there was a significant difference between each concentration. 
An F-ratio test determined that the dual extraction of ll.-9-THC and ll.-9-THCA gave 
concentrations that had no significant differences. The F-ratio for /l.-9-THC 
concentrations was 0.191, while the F-ratio for /l.-9-THCA concentrations was 0.021 . 
Both fell under the critical value of F for the analysis of variance from the table which 
was 5.08 for a 0.01 level of significance. This showed that the concentrations of ll.-9-
THC and 8-9-THCA calculated for each sample's three aliquots were all significantly 
similar. 
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With a single extraction of both 8-9-THC and 8-9-THCA, analysts are able 
perform maximal tests in a shorter period of time, while also lowering the amount of 
materials required. This will allow forensic toxicology laboratories to save time and 
money and have a higher throughput when analyzing urine for 8-9-THC and 8-9-THCA. 
Future research in this area should focus on analyzing the specific timing of the 
metabolism of 8-9-THC to 8-9-THCA and their excretion in urine so that impairment 
may be more accurately determined. 
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1. Proiect Goals: 
APPENDIXB 
RESEARCH PROTOCOL 
To develop and validate a time and cost efficient technique for the 
simultaneous extraction of both L\-9-Tetradydrocannabinol and 11-Nor-
Carboxy-L\-9-Tetrahydrocannabinol from urine at an acidic pH. 
2. Protocols: 
Samples to be collected: 
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• No urine samples will be collected by the principle investigator. Urine 
samples available in the Forensic Chemistry laboratory used for earlier 
IRB approved projects (Protocol Number 10020801) will be used for 
this study. 
Subject Population: 
• Approximately 20 samples are available in the laboratory consisting of 
both male and female sources, all above the age of 18. 
Brief Experimental Procedure: 
• Urine samples will be divided into three, two milliliter aliquots and 
buffered with sodium phosphate. 
• Separate incubations with J3-glucuronidase and sodium hydroxide will 
be administered in order to break the glucuronide bonds. 
• Liquid-liquid Extraction will be performed with hexane:ethyl acetate 
(4:1). 
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• Samples will be derivatized with N-Methyl-N-(t-butyldimethylsilyl) 
trifluoroacetamide (MTBSTF A) + 1 % tertbutyldimetheylchlorosilane 
(t-BDMCS) Bis(trimethylsilyl)trifluoroacetamide (BSTFA). 
• Analysis will be performed with Gas Chromatography/Mass 
Spectrometry (Claros 600 EI\ Perkin Elmer, Shelton, CT). 
Research Locations 
• Research and analysis of results will be conducted in the Forensic 
Chemistry laboratory, School of Criminal Justice, University of 
Southern Mississippi. 
3. Benefits: 
There are no predetermined benefits for individuals who anonymously 
provided the samples. 
4. Risks: 
Sampling Risks: 
• None 
Confidentiality and Anonymity: 
• All information regarding samples from Protocol 100200801 have 
been destroyed. All samples remain anonymous. 
5. Informed Consent: 
Not applicable since no samples will be collected from any individuals for this 
study. 
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